Nexsen Appoints Global Clinical Leader, Professor Shekhar Kumta, to Board
Jane Morgan Management
3 December 2025 – Perth, Australia | Nexsen Limited (ASX:NXN) has today announced the appointment of internationally recognised surgeon-scientist, Professor Shekhar Kumta, as a Non-Executive Director. Professor Kumta brings more than 45 years’ experience across Australia and Hong Kong, with senior faculty, hospital governance and medical leadership roles spanning major institutions including the Chinese University of Hong Kong, Prince of Wales Hospital, and The Northern Hospital (Victoria).
This appointment strengthens Nexsen’s clinical, regulatory and commercial capability as the Company progresses clinical validation of its lead GBS Rapid point-of-care sensor and advances its broader rapid diagnostics platform towards international market entry in the second half of calendar year 2026.
With significantly enhanced leadership, the Company’s access to major health systems and creates immediate entry points for early evaluation and commercial discussions through Professor Kumta’s long-standing relationships with clinicians, hospital groups and research collaborators across Hong Kong, India and NHS-linked networks in the United Kingdom. These relationships are necessary to support the Company’s strategy to accelerate adoption of point-of-care technologies in maternal health and renal medicine across key markets. 
Professor Kumta’s senior clinical leadership standing is hoped to significantly enhance its global regulatory and market-entry pathways, leading to better engagement with regulators and health technology assessors across the United States, United Kingdom, Europe and Asia as it prepares for US FDA 510(k) pathway engagement, including pre-submission planning and data-package preparation. 
Professor Shekhar Kumta, Non-Executive Director, commented: “Having worked across global health systems for nearly 5 decades, I have never seen a solution for quickly diagnosing time-critical diseases like Nexsen’s suite of point-of-care diagnostics. The diagnostics appear to be a breakthrough with tremendous opportunity for international adoption and real-world clinical impact.
This global perspective is particularly relevant as health systems increasingly prioritise faster, decentralised diagnostics to reduce patient delays, improve triage efficiency and manage rising chronic disease burdens.
I am particularly excited about Nexsen’s emerging suite of Kidney Function Tests for the early detection of Acute Kidney Injury and for monitoring renal dysfunction at home using laboratory-grade point-of-care tests. The ability to move beyond delayed, creatinine-based detection towards sensitive, actionable biomarkers has the potential to transform kidney care, prevent avoidable harm, and meaningfully improve patients’ quality of life.
These biomarkers represent a significant advancement in early detection, with the potential to become the standard-of-care pathways in emergency, renal and primary-care settings.
What motivates me most is that Nexsen’s platform is being designed to make sophisticated biomarker testing simple, rapid and truly point-of-care. By enabling easy testing of biomarkers that need timely bedside or home-based detection, this technology can empower clinicians with faster, more confident decision-making and support patients and families in managing complex conditions outside of hospital.
I am very pleased to join Nexsen at this pivotal stage and look forward to supporting the team as it advances from clinical validation to global commercial rollout.“
Nexsen’s Managing Director, Mark Muzzin, commented: “Professor Kumta’s appointment provides Nexsen with world-class clinical leadership and direct access to international healthcare networks. His experience aligns perfectly with our regulatory and revenues roadmap for our kidney diagnostics platform and supports our transition from clinical validation to commercial execution and partnership engagement.
We are pleased to welcome him at a time when the Company is building significant momentum toward global market entry, including preparation for US FDA 510(k) submission, international regulatory pathways and scaled manufacturing.”
Nexsen’s Chair, Reece O’Connell, commented: “We are delighted to welcome Professor Kumta to the Board. His extensive international influence and experience integrating medical technologies into clinical practice significantly enhance Nexsen’s capability to scale globally.
His contribution will be instrumental as we advance toward key regulatory, clinical and commercial milestones and progress toward key regulatory and market-access milestones.
His appointment further strengthens the Board as Nexsen prepares for a phase of accelerated growth, international expansion and sustained shareholder value generation.”
Professor Kumta’s appointment is aligned with the Company’s strategy for a transition from development-stage to commercial readiness and its pathway toward anticipated international market entry from 2H CY2026.
About us:
ABOUT NEXSEN LIMITED (ASX:NXN)
Nexsen is developing a suite of rapid point-of-care diagnostics that deliver lab-grade results for conditions that have traditionally relied on delayed lab testing. The company focuses on areas of significant unmet clinical need, where faster answers can improve patient outcomes and reduce pressure on healthcare systems.
Nexsen’s lead diagnostic is the GBS Rapid Sensor, a rapid point-of-care diagnostic for detecting Group B Streptococcus, addressing a critical unmet need in maternal health. The company is also developing rapid kidney function tests for Acute Kidney Injury and Chronic Kidney Disease, two conditions that affect more than 850 million people globally and remain underserved by slow, lab-based diagnostics.
With further diagnostics in development across human health, ag-tech and biosecurity, Nexsen aims to become a global leader in rapid point-of-care diagnostics, delivering on its mission to ensure every person benefits from a Nexsen test at some point in their life.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]